Core Viewpoint - MicroPort Scientific Corporation (02172) announced changes in its board of directors, with Dr. Chang Zhao Hua resigning as non-executive director and chairman of the board to focus on other business commitments, while Mr. Sun Qing Wei also resigned for similar reasons. Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board, and Mr. Liu Xu Dong has been appointed as a non-executive director [1] Group 1 - Dr. Chang Zhao Hua resigned from his position to allocate more time to other business activities [1] - Mr. Sun Qing Wei also resigned from his role for similar reasons [1] - Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board [1] Group 2 - Mr. Liu Xu Dong has been appointed as a non-executive director [1]

Core Viewpoint - Micron Brain Science (02172.HK) announced the resignation of Chang Zhaohua as non-executive director and chairman of the board due to the need to allocate more time to other business commitments [1] - Sun Qingwei also resigned as non-executive director for similar reasons [1] - Zhang Jie has been appointed as the new non-executive director and chairman of the board, while Liu Xudong has been appointed as a non-executive director [1] Summary by Categories - **Management Changes** - Chang Zhaohua resigned as non-executive director and chairman of the board [1] - Sun Qingwei resigned as non-executive director [1] - Zhang Jie appointed as non-executive director and chairman of the board [1] - Liu Xudong appointed as non-executive director [1]

MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 | 張劼博士 | （非執行董事兼董事會主席） | | --- | --- | | 謝志永先生 | （執行董事） | | 王亦群先生 | （執行董事） | | 劉旭東先生 | （非執行董事） | | 吳夏女士 | （非執行董事） | | 張海曉博士 | （獨立非執行董事） | | 樊欣先生 | （獨立非執行董事） | | 李志勇先生 | （獨立非執行董事） | 董事會設立三個委員會。下表提供各董事會成員於該等委員會中所擔任的職位。 | | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 張劼博士 | | | | | | ...

Core Viewpoint - MicroPort Scientific Corporation (02172) announced changes in its board of directors, with Dr. Chang Zhao Hua resigning as non-executive director and chairman to focus on other business commitments, while Mr. Sun Qing Wei also resigned for similar reasons. Dr. Zhang Jie has been appointed as the new non-executive director and chairman, and Mr. Liu Xu Dong has been appointed as a non-executive director [1] Group 1 - Dr. Chang Zhao Hua resigned from his position as non-executive director and chairman of the board [1] - Mr. Sun Qing Wei also resigned from his role as non-executive director [1] - Dr. Zhang Jie has been appointed as the new non-executive director and chairman of the board [1] Group 2 - Mr. Liu Xu Dong has been appointed as a non-executive director [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由微創腦科學有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.51(2)條而作出。 本公司董事（「董事」）會（「董事會」）宣佈，以下董事會變動自二零二五年十一 月十四日起生效： 非執行董事及董事會主席辭任 常兆華博士（「常博士」）因需投放更多時間於其他業務而辭任非執行董事及董 事會主席。孫慶蔚先生（「孫先生」）因需投放更多時間於其他業務而辭任非執 行董事。常博士及孫先生已向本公司確認，彼等與董事會概無意見分歧。本公 司確認，概無有關常博士及孫先生辭任之事宜須敦請本公司股東垂注。本公司 謹此感謝常博士及孫先生在擔任非執行董事期間對本集團所作之努力及寶貴 貢獻，並期待彼等日後就本集團發展持續提供專業指導、建議及意見。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 ...

Core Viewpoint - The brain-computer interface (BCI) concept stocks in the Hong Kong market have shown strong performance, driven by the advancement of a domestically developed implantable wireless BCI system entering a special review process by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this technology [1][2]. Group 1: Market Performance - Brain动极光-B has increased by over 9%, with a latest price of 6.960 and a total market capitalization of 8.813 billion [2] - 微创脑科学 has risen by over 4%, with a latest price of 11.880 and a total market capitalization of 6.843 billion [2] - 南京熊猫电子股份 has gained nearly 3%, with a latest price of 5.140 and a total market capitalization of 4.697 billion [2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive BCI product to enter the "green channel" for innovative medical devices in China, indicating a key transition from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing a significant rise, driven by advancements in technology and supportive regulatory developments in China [1] Group 1: Market Performance - Brain-machine concept stocks have collectively surged, with notable increases: Brainhole Aurora (06681) up 8.49% to HKD 6.9, Nanjing Panda Electronics (00553) up 3.2% to HKD 5.16, and Microneuroscience (02172) up 4.39% to HKD 11.9 [1] Group 2: Regulatory Developments - On November 11, Shanghai Ladder Medical Technology Co., Ltd.'s "implantable wireless brain-machine interface system" entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA), marking it as the first invasive brain-machine interface product to enter this "green channel" in China [1] - The NMPA has also released the YY/T 1987—2025 standard for medical devices utilizing brain-machine interface technology, indicating a formalization of industry standards [1] Group 3: Industry Outlook - Dongwu Securities expresses optimism regarding the domestic policy support and accelerated clinical and commercial progress in the brain-machine interface industry [1] - Huafu Securities notes that advancements in brain science, artificial intelligence, medicine, cognitive neuroscience, and psychology are enriching the scope of brain-machine interfaces, highlighting multiple advantages for the development of this industry in China [1]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive BCI product entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices [1][2] - Clinical practices for BCIs in China are accelerating, with several hospitals initiating clinical applications and trials, positioning China as the second country globally to enter the clinical trial phase for invasive BCIs [3] Industry Developments - The BCI industry is expected to achieve key technological breakthroughs by 2027, establishing an advanced technical, industrial, and standard system, with a goal of nurturing globally influential companies by 2030 [2] - The BCI market is projected to grow significantly, with estimates indicating a market size of approximately $2.62 billion in 2024, reaching $2.94 billion by 2025, and potentially growing to $12.4 billion by 2034 [4] Clinical and Commercial Progress - Major hospitals in China are launching BCI clinical applications, with initiatives such as the first BCI outpatient clinic in Central China and the establishment of specialized clinical wards for BCI technology [3] - The development of BCI technology is seen as a beacon of hope for over 3 billion people suffering from neurological disorders globally [3] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Nanjing Panda Electronics is also engaged in BCI technology development, focusing on multimodal human-computer interaction systems [5]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive wireless BCI system entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices, which provides a unified framework for development and regulation [1][2] - By 2027, breakthroughs in key BCI technologies are expected to establish an advanced technical, industrial, and standard system, with the goal of nurturing globally influential companies by 2030 [2] Industry Developments - Clinical practices for invasive BCIs in China are accelerating, with the country becoming the second globally to enter clinical trial phases after the United States [3] - Major hospitals are launching BCI clinical applications, indicating a shift from research-driven to clinically-driven development in the BCI field [3] - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $2.94 billion in 2025, with expectations to reach $12.4 billion by 2034 [4] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Heartway Medical is set to begin formal clinical trials for its invasive BCI project by the end of 2026, following successful animal testing [5] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, indicating ongoing innovation in the sector [5]

Group 1 - MicroPort Scientific Corporation reduced its stake in MicroPort NeuroScience (02172) by 19 million shares at a price of HKD 10.25 per share, totaling approximately HKD 194.75 million [1] - After the reduction, MicroPort Scientific Corporation's remaining shareholding is approximately 235.9 million shares, representing a holding percentage of 40.32% [1]